Ongoing activity of meropenem against European isolates: report on the MYSTIC 2005 results

Abstract number: 1733_1305

Turner P.

Objectives: MYSTIC (Meropenem Yearly Suceptibility Test Information Collection) is a longitudinal global surveillance Study that has examined annually the in vitro activity of meropenem and other broad spectrum agents against clinically significant, non-copy isolates since 1997. The data presented here covers the year 2005 and deals with isolates from Europe.

Methods: A total of 7710 isolates from centres in Belgium, Bulgaria, Croatia, Czech Republic, Finland, Germany, Greece, Malta, Poland, Russia, Spain, Sweden, Turkey and the UK were tested by CLSI reference methodology (either agar dilution or broth microdilution) and associated interpretative criteria. Extended-spectrum b-lactamase (ESBL) were confirmed by synergy with clavulanic acid and AmpC by lack of synergy with this compound.

Results: See the table.

Organism (n)Percent suceptibility
Staphylococci (1326)99999658978693
Enterobacteriaceae (3718)99988282878287
P. aeruginosa (1098)75677872616662
A. baumannii (408)60582322202741
aMEM, meropenem; IPM, imipenem; P+T: piperacillin + tazobactam; CAZ, ceftazidime; CPM, cefepime; CIP, ciprofloxacin; GM, gentamicin.

Conclusions: Meropenem, as in 1997, remains the antibiotic with the broadest spectrum of activity followed by imipenem. Many of the other comparators are experiencing considerable drops in their in vitro effectiveness indicating the need for continued surveillance.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Location: ICC, Munich, Germany
Presentation type:
Back to top